NASDAQ · XNCR
Xencor, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for XNCR: Nov 4, 2026
Xencor, Inc. Common Stock is estimated to report earnings on 11/04/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 7 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.35. The reported EPS for the same quarter last year was $-0.08.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.35 | $0.22 | $-1.21 | 7 |
| Dec 2026 | $-0.93 | $-0.55 | $-1.26 | 6 |
| Mar 2027 | $-1.01 | $-0.67 | $-1.20 | 5 |
| Jun 2027 | $-0.99 | $-0.45 | $-1.25 | 5 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · MarketBeat · Fintel · The Motley Fool- RTTNews · Oct 26, 3:25 PM EDTThree Movers And A Catalyst: SGRY, XNCR, ORKA Gain As Acumen Nears ALTITUDE-AD Readout(RTTNews) – Shares of several biotech companies moved sharply higher following corporate and clinical developments. Surgery Partners surged on reports of a late-stage buyout talks with Bon Secours Mercy Health, Xencor rallied on updated Phase 1 data for XmAb819 in kidney cancer,
- MarketBeat · Oct 26, 3:02 PM EDTXencor Picks Phase 3 Dose After XmAb819 Shows 45.5% Response Rate in Kidney CancerXencor (NASDAQ:XNCR) reported updated Phase 1 dose-expansion results for its ENPP3-targeting CD3 T-cell engager, XmAb819, in previously treated advanced clear cell renal cell carcinoma at the ESMO 2026 conference. The company said it selected a 400 microgram-per-kilogram intraven
- Fintel · Oct 26, 10:03 AM EDTXencor, Inc. Selects 400 mcg/kg as Proposed Recommended Phase 3 Dose for XmAb819 in Advanced Clear Cell Renal Cell CarcinomaXencor, Inc. announced updated results from its Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with advanced clear cell renal cell carcinoma. Based on these results, the company selected 400 mcg/kg as the proposed intravenous recommended
- The Motley Fool · Aug 31, 5:04 AM EDTJohnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.J&J's portfolio primarily includes small biotech and medtech companies.
- BNK Invest · Aug 26, 8:59 AM EDTXencor Reaches Analyst Target PriceIn recent trading, shares of Xencor, Inc (Symbol: XNCR) have crossed above the average analyst 12-month target price of $29.00, changing hands for $29.33/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuatio
- RTTNews · Aug 13, 4:28 AM EDTBiotech Stocks At 52-Week Highs – BIVI +22%, XNCR, ANRO, HAE, ACAD(RTTNews) – The following biotech stocks reached a 52-week high on August 12, 2026, driven up by key catalysts such as positive quarterly reports or promising results from clinical trials.
- Zacks · Aug 5, 5:25 PM EDTXencor (XNCR) Reports Q2 Loss, Beats Revenue EstimatesXencor (XNCR) delivered earnings and revenue surprises of +64.63% and +337.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Jul 31, 6:57 AM EDTBiotech Stocks At 52-Week Highs- CORT +30%, NEOG +22% & BAX +7% With Quarterly Results, TRAX, XNCR(RTTNews) – The following biotech stocks reached 52-week highs on July 30, 2026, driven by key catalysts such as positive quarterly reports or announced settlement agreements.
- RTTNews · Jul 22, 5:44 AM EDTBiotech Stocks At 52-Week Highs – CPHI Soars +790%, XNCR, ETON, TXG, ACHC(RTTNews) – The following biotech stocks reached 52-week highs on July 21, 2026, due to reports on the progress of clinical trials or upcoming quarterly financial results.
- RTTNews · Jul 21, 3:41 AM EDTBiotech Stocks At 52-Week Highs – XNCR, COAG, MNPR, SOPH, ACRS(RTTNews) – The following biotech stocks reached a 52-week high on July 20, 2026, driven by key catalysts such as upcoming clinical trial launches and the prospective release of data from these studies.
- Zacks · Jul 20, 7:26 AM EDTXencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock?Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- Zacks · May 6, 5:10 PM EDTXencor (XNCR) Reports Q1 Loss, Lags Revenue EstimatesXencor (XNCR) delivered earnings and revenue surprises of -164.58% and -75.38%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Xencor, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.